Using a QbD approach in the development and formulation of topical products will enable the drug developer to provide a robust control strategy for manufacturing.
Sarah Pratt
Advertisement
Sarah Pratt is chief operating officer at MedPharm.
Articles by Sarah Pratt
Using a QbD approach in the development and formulation of topical products will enable the drug developer to provide a robust control strategy for manufacturing.
Advertisement
Latest Updated Articles
QbD Strategies to Secure the Scale-Up of Semi-Solid Topical FormulationsSeptember 2nd 2018
Process Development Best Practices for Topical Drug ProductsFebruary 2nd 2019
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs
2
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
3
Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
4
A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision
5